Literature DB >> 11522003

Impairment of the plasmin activation system in primary pulmonary hypertension: evidence for gender differences.

G Christ1, S Graf, R Huber-Beckmann, G Zorn, I Lang, M Kneussi, B R Binder, K Huber.   

Abstract

Primary pulmonary hypertension (PPH) is a rare disorder, with marked in-situ thrombosis of small pulmonary vessels occurring primarily in adult women. We investigated whether differences in the plasmin- and thrombin activation system are associated with the predominate affection of females. Plasma levels of plasminogen activator inhibitor type 1 (PAI-1), tissue-type plasminogen activator (t-PA), fibrinogen, thrombin-antithrombin (TAT) complexes, and prothrombin fragments (F1.2) were measured at baseline and after standardized venous occlusion (VO) in patients with PPH (24 female, 9 male). At baseline, females showed significant higher TAT levels (p = 0.05), higher t-PA antigen levels (p = 0.01) and higher fibrinogen levels (p = 0.03) with positive correlation to mean pulmonary artery pressure (mPAP), as well as nonsignificant lower t-PA activity, higher PAI-1 antigen and activity and F1.2 levels. After VO, females showed a significantly blunted increase in t-PA antigen (p = 0.01) and t-PA activity (p = 0.001), correlating with mPAP, as well as increased PAI-1 activity (p = 0.05). We hypothesize, that the observed presence of gender differences in the plasmin- and thrombin activation system in PPH leading to an antifibrinolytic/prothrombotic state might, in part, explain the female predominant incidence of this disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11522003

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Matrix metalloproteinase-9 and plasminogen activator inhibitor-1 are associated with right ventricular structure and function: the MESA-RV Study.

Authors:  Steven M Kawut; R Graham Barr; W Craig Johnson; Harjit Chahal; Harikrishna Tandri; Aditya Jain; Michael R Bristow; Jorge R Kizer; Emilia Bagiella; Joao A C Lima; David A Bluemke
Journal:  Biomarkers       Date:  2010-10-05       Impact factor: 2.658

2.  t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.

Authors:  Sujana Katta; Shivani Vadapalli; B K S Sastry; Pratibha Nallari
Journal:  Indian J Hum Genet       Date:  2008-05

Review 3.  The Serpin Superfamily and Their Role in the Regulation and Dysfunction of Serine Protease Activity in COPD and Other Chronic Lung Diseases.

Authors:  Gillian A Kelly-Robinson; James A Reihill; Fionnuala T Lundy; Lorcan P McGarvey; John C Lockhart; Gary J Litherland; Keith D Thornbury; S Lorraine Martin
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

4.  Markers of thrombogenesis and fibrinolysis and their relation to inflammation and endothelial activation in patients with idiopathic pulmonary arterial hypertension.

Authors:  Grzegorz Kopeć; Deddo Moertl; Sabine Steiner; Ewa Stępień; Tomasz Mikołajczyk; Jakub Podolec; Marcin Waligóra; Jakub Stępniewski; Lidia Tomkiewicz-Pająk; Tomasz Guzik; Piotr Podolec
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

Review 5.  TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family.

Authors:  Nina Rol; Konda Babu Kurakula; Chris Happé; Harm Jan Bogaard; Marie-José Goumans
Journal:  Int J Mol Sci       Date:  2018-08-31       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.